Natera To Present New Data at ACMG Annual Meeting
Study results demonstrate value of SNP-based non-invasive prenatal testing, expanded carrier screening, and embryo and miscarriage tissue testing across various genetic conditions
SAN CARLOS, Calif., April 10, 2018 /PRNewswire/ — Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, will present new data that demonstrate the value of its unique single nucleotide polymorphism (SNP)-based technology and the benefits of expanded carrier screening at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Charlotte, N.C., April 10–14, 2018 (booth No. 1501).
Natera will present three educational posters and one platform presentation at ACMG focused on prenatal genetic screening, which include findings for disorders in sexual development, patient perspectives on Duchenne muscular dystrophy carrier screening, and determination of aneuploidy rates spanning pregnancy from embryo stage to products of conception.
- Thursday, April 12, 2018
- 10–11:30 a.m.—Poster #763: Evaluating Etiology of Possible X Chromosome Aneuploidy Cases Detected on Carrier Screening by Utilizing SNP-based Non-Invasive Prenatal Testing Outcome Data. Presented by Valerie Kantor, Medical Science Liaison
- 10–11:30 a.m.—Poster #535: Duchenne Muscular Dystrophy Carrier Screening: Perspectives from Screen-Positive Patients. Presented by Carrie Couyoumjian, Genetic Counselor
- Friday, April 13, 2018
- 4:15–4:30 p.m.—Platform presentation #42: Chromosome Aneuploidy Rates Spanning Pregnancy: Analysis of Molecular Chromosome Results in Blastocyst-Staged Embryos and Products of Conception Samples. Presented by Katrina Merrion, Senior Genetic Counselor Manager
- 10:30 a.m.–12 p.m.—Poster #776: Fetal Sex Discrepancy Between Single-Nucleotide Polymorphism-Based NIPT and Ultrasound or Clinical Phenotype. Presented by Rupin Dhamankar, Senior Medical Science Liaison
Natera is a global leader in cell-free DNA testing. The mission of the company is to transform the diagnosis and management of genetic diseases. Natera operates an ISO 13485-certified and CAP-accredited CLIA laboratory in San Carlos, Calif. It offers a host of proprietary genetic testing services to inform physicians who care for pregnant women, researchers in cancer including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. Follow Natera on LinkedIn and Twitter.
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, our ability to successfully increase demand for and grow revenues for our product offerings, whether the results of clinical studies will support the use of our product offerings, our expectations of the reliability, accuracy and performance of our screening tests, or of the benefits of our screening tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov